Hover Image To Zoom

Asuragen | Armored RNA Quant® SARS-CoV-2 Control

Armored Controls have been utilized in IVD-approved assays for more than 20 years and continue to serve as an important tool in the rapidly evolving space of molecular diagnostics.

In response to the worldwide outbreak of COVID-19, Asuragen has developed a novel Armored RNA control that targets the SARS-CoV-2 viral nucleocapsid (N) region. Our new RNAse P construct aligns with the CDC and WHO recommended Diagnostic Panel (CDC-006-00019) providing a stable, reliable, and safe way to rapidly test for the presence of the novel Coronavirus.

Each control encodes an in vitro transcribed RNA encapsulated in a protective protein coat to create a virus-like particle resistant to nuclease degradation. This allows the products to be used as RNA extraction controls, process quality controls, or positive diagnostic reference controls. From feasibility to clinical use, these robust and versatile controls are beneficial across all sectors of the research and diagnostic spectrum.

Enquiry Download catalog Back to Listing
  • Features

Tab 0

  • Available as standalone catalog items
  • High-quality solution to monitor extraction and process efficiency
  • Compatible with a wide range of RNA-based clinical assays
  • Non-infectious, synthetic constructs simplify shipping and storage
  • Deployable as extractable, exogenous internal positive control
  • Tailored sequences specific to SARS-CoV-2 and RNAse P
  • Degradation resistant in majority of biological matrices
  • Multiple volume and manufacturing options available
  • Available as cGMP or development lot in a range of fill volumes
  • Concentration determined using National Institute of Standards (NIST)traceable standard
  • Highly standardized, quality controlled manufacturing ensures reliabilityand consistency between lots
  • Manufactured in a cell-free system